UAE, Merck Serono, Neopharma form first pharmaceutical production agreement

Wednesday, December 5, 2012 11:35 AM

Merck Serono, a division of Germany-based Merck, and a local manufacturer, Neopharma, have formed the first partnership of its kind to locally produce Merck branded medication in the UAE for distribution across the Middle East.

Merck Serono will be the first multinational pharmaceutical company to work with a local manufacturer to cater to regional demand for key pharmaceutical products through export out of the UAE manufacturing base. Initially, two Merck Serono products will be manufactured by Neopharma: Euthyrox , a hormone therapy requiring a very stringent sterile environment for production and packaging, and Glucophage, a standard oral treatment for people suffering from type 2 diabetes that helps control blood sugar levels. Production of both branded medications will begin in 2013.

"Currently valued at approximately 1.4 billion and growing at 6.8% annually, the UAE pharmaceutical market is one of the most developed markets in the Middle East, with a strong healthcare infrastructure and the highest per-capita medicine expenditure in the region,” said Sheikh Nahyan bin Mubarak Al Nahyan, chairman of Neopharma and Minister of Higher Education and Scientific Research. "This partnership characterizes our country's rapidly developing healthcare industry and improved production capabilities, putting it on-par with international standards of pharmaceutical production."

Stefan Oschmann, CEO of Merck Serono, said, “After careful consideration of the production capabilities of various companies across the Middle East, we identified Neopharma as having the most advanced, European-standard manufacturing facilities capable of producing significant quantities of both hormone and regular pharmaceutical drug products.”

Traditionally the local manufacturing sector in the UAE has been relatively small and focuses on basic medicines. Until this alliance, the market relied on imports for pharmaceutical prescriptions. In 2010, nearly 64% of pharmaceutical imports came from Europe, around 8% from North America and another 8% from the MENA region.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs